William Blair initiates coverage of digital finance stocks
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
Stock Trading Recap. On Friday, Tenaya Therapeutics Inc (TNYA) stock saw a modest uptick, ending the day at $1.4 which represents a slight increase ...
Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...
William Blair International Growth Fund earns an Average Process Pillar rating. The most important driver of the rating is the stability of the management team. Specifically, the fund has not seen ...
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...
William Blair analyst Andrew Jeffrey initiated coverage of SoFi Technologies (SOFI) with an Outperform rating and no price target The firm ...
BofA Securities has recently reduced FibroGen Inc (FGEN) stock to Underperform rating, as announced on August 8, 2023, according to Finviz. Earlier, on June 26, 2023, William Blair had reduced the ...
Portillo’s has never been one to follow the worn path in quick service. It hasn’t engaged in the “value wars” or materially ...
Enfusion (ENFN – Research Report) received a Hold rating and price target from William Blair analyst Dylan Becker today. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback